196 related articles for article (PubMed ID: 31889141)
1. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Ikemura K; Hiramatsu SI; Shinogi Y; Nakatani Y; Tawara I; Iwamoto T; Katayama N; Okuda M
Sci Rep; 2019 Dec; 9(1):20359. PubMed ID: 31889141
[TBL] [Abstract][Full Text] [Related]
2. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
Mitsuboshi S; Niimura T; Kanda M; Ishida S; Zamami Y; Ishizawa K
Ann Pharmacother; 2022 Aug; 56(8):910-915. PubMed ID: 34726078
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
[TBL] [Abstract][Full Text] [Related]
4. Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches.
Moriyama A; Ueda H; Narumi K; Asano S; Furugen A; Saito Y; Kobayashi M
Expert Opin Drug Metab Toxicol; 2024 May; 20(5):399-406. PubMed ID: 38706380
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
7. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Kataoka H; Yang K; Rock KL
Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
Markowicz-Piasecka M; Huttunen J; Montaser A; Adla SK; Auriola S; Lehtonen M; Huttunen KM
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299347
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
[TBL] [Abstract][Full Text] [Related]
11. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
12. Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2.
El-Sheikh AA; Morsy MA; Al-Taher AY
Fundam Clin Pharmacol; 2016 Oct; 30(5):406-18. PubMed ID: 27213989
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
14. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
15. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
16. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
Kobayashi S; Yasu T; Momo K; Ohno N
Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of Hepatic Damage Induced by Anticancer Drug Methotrexate by Zobo (Hibiscus sabdariffa extract) Supplementation via Targeting Oxidative Hepatotoxicity in Rats.
Famurewa AC; Folawiyo AM; Epete MA; Igwe EC; Okike PI; Maduagwuna EK
J Diet Suppl; 2019; 16(3):318-330. PubMed ID: 29672189
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
20. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
